(P-1116) Distribution of Rifaquizinone in Bone, Synovial Fluid and Plasma: A Phase 1 Trial in Patients Undergoing Total Hip or Knee Arthroplasty

Friday, October 18, 2024

12:15 PM – 1:30 PM US PT

Location: Halls JK

Co-Author(s)

JP

Javad Parvizi, MD, FRCS

Rothman Orthopaedic Institute
Philadelphia, Pennsylvania, United States
CK

Chad A Krueger, MD

Rothman Orthopaedic Institute
Philadelphia, Pennsylvania, United States
Jing Chen, Master of Science (she/her/hers)

VP Clinical Operation
TenNor Therapeutics （Suzhou） Ltd
Suzhou, Jiangsu, China (People's Republic)
Huan Wang, PhD (she/her/hers)

Director of pharmacology and toxicology
TenNor Therapeutics (Suzhou) Ltd
Suzhou, Jiangsu, China (People's Republic)
CA

Changlin Ai, Master of Medicine

TenNor Therapeutics (Suzhou) Ltd
Suzhou, Jiangsu, China
GG

Guozhu Geng, MD

TenNor Therapeutics (Suzhou) Ltd
Suzhou, Jiangsu, China

Zhenkun Ma, PhD (he/him/his)

CEO
TenNor Therapeutics
Suzhou Industrial Park, Jiangsu, China (People's Republic)